475481-63-1

Upstream product

• 122-03-2 (4-isopropylbenzaldehyde) 
• 870539-64-3 4,5-dimethyl-2-(4-(2-propyl)-phenyl)-oxazole 3-oxide 

Downstream Products

• 752212-86-5 4-iodomethyl-5-methyl-2-(4-(2-propyl)-phenyl)-oxazole 
• 1226268-85-4 C₁₅H₁₆N₂O 
• 475481-62-0 [rac]-2-ethoxy-3-{4-[2-(4-isopropyl-phenyl)-5-methyl-oxazol-4-ylmethoxy]-5,6,7,8-tetrahydro-naphthalen-1-yl}-propionic acid ethyl ester 

Relevant academic research and scientific papers

Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes

Design, synthesis, and SAR of novel α-alkoxy-β-arylpropionic acids as potent and balanced PPARαγ coagonists are described. One representative thereof, Aleglitazar ((S)-2Aa), was chosen for clinical development. Its X-ray structure in complex with both receptors as well as its high efficacy in animal models of T2D and dyslipidemia are also presented.

Structure-based design of indole propionic acids as novel PPARα/γ co-agonists

In the quest for novel PPARα/γ co-agonists as putative drugs for the treatment of type 2 diabetes and dyslipidemia, we have used a structure-based design approach to identify propionic acids with a 1,5-disubstituted indole scaffold as potent PPARα/γ activ

Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals

Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, in which the radicals are as defined, and their physiologically acceptable salts an

Indolyl derivatives as liver-X-receptor (LXR) modulators

The invention relates to compounds of formula (I): and pharmaceutically acceptable salts and pharmaceutically acceptable esters thereof, wherein R1, R2, R3, R4, R5, R6, A, m, n and p are defined as in claim 1. These compounds can be used as pharmaceutical compositions for the treatment of, for example, diabetes.